Combined effects of progesterone and SOCS3 DNA methylation on T2DM: a case-control study.
Adult
Aged
Case-Control Studies
China
/ epidemiology
DNA Methylation
/ drug effects
Diabetes Mellitus, Type 2
/ drug therapy
Female
Humans
Logistic Models
Male
Middle Aged
Prevalence
Progesterone
/ administration & dosage
Risk Factors
Rural Population
/ statistics & numerical data
Suppressor of Cytokine Signaling 3 Protein
/ administration & dosage
Combined effect
Methylation
Progesterone
Suppressor of cytokine signaling 3
Type 2 diabetes mellitus
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
26 09 2021
26 09 2021
Historique:
received:
12
07
2021
accepted:
14
09
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
19
2
2022
Statut:
epublish
Résumé
This study aims to investigate the independent and combined effects of progesterone and suppressor of cytokine signaling (SOCS)-3 DNA methylation on type 2 diabetes mellitus (T2DM) among men and postmenopausal women in rural China. A case-control study with 914 participants (329 T2DM, 585 controls) was conducted. Serum progesterone was detected with liquid chromatography-tandem mass spectrometry. DNA methylation of SOCS3 was determined by MethylTarget™. Linear regression was applied to evaluate the associations of progesterone and SOCS3 methylation with marks of glucose metabolism. Logistic regression was employed to investigate the independent and combined effects of progesterone and SOCS3 methylation with T2DM in men and postmenopausal women. After multiple adjustment, progesterone was positively associated with T2DM in both men (odds ratio (OR) (95% confidence interval (CI)): 2.77 (1.79, 4.29)) and postmenopausal women (OR (95% CI): 1.85 (1.26, 2.72)). Methylation level of Chr17:76,356,190 or Chr17:76,356,199 (SOCS3) was negatively associated with T2DM in both men (OR (95% CI): 0.58 (0.39, 0.86) or 0.27 (0.14, 0.51)) and postmenopausal women (OR (95% CI): 0.43 (0.29, 0.65) or 0.53 (0.28, 0.99)). Subjects with high progesterone and low Chr17:76,356,190 or Chr17:76,356,199 methylation were more susceptible to have a higher prevalence of T2DM (men: OR (95% CI): 5.20 (2.49, 10.85) or 5.62 (2.74, 11.54); postmenopausal women: OR (95% CI): 3.66 (1.85, 7.26) or 3.27 (1.66, 6.45)). The independent and combined effects of progesterone and SOCS3 methylation on T2DM were found among men and postmenopausal women, suggesting that ensuring low levels of progesterone and high methylation of SOCS3 could reduce the prevalence of T2DM. Trial registration The Chinese Clinical Trial registration: The Henan Rural Cohort Study, ChiCTR-OOC-15006699. Registered 06 July 2015, http://www.chictr.org.cn/showproj.aspx?proj=11375.
Sections du résumé
BACKGROUND
This study aims to investigate the independent and combined effects of progesterone and suppressor of cytokine signaling (SOCS)-3 DNA methylation on type 2 diabetes mellitus (T2DM) among men and postmenopausal women in rural China.
METHODS
A case-control study with 914 participants (329 T2DM, 585 controls) was conducted. Serum progesterone was detected with liquid chromatography-tandem mass spectrometry. DNA methylation of SOCS3 was determined by MethylTarget™. Linear regression was applied to evaluate the associations of progesterone and SOCS3 methylation with marks of glucose metabolism. Logistic regression was employed to investigate the independent and combined effects of progesterone and SOCS3 methylation with T2DM in men and postmenopausal women.
RESULTS
After multiple adjustment, progesterone was positively associated with T2DM in both men (odds ratio (OR) (95% confidence interval (CI)): 2.77 (1.79, 4.29)) and postmenopausal women (OR (95% CI): 1.85 (1.26, 2.72)). Methylation level of Chr17:76,356,190 or Chr17:76,356,199 (SOCS3) was negatively associated with T2DM in both men (OR (95% CI): 0.58 (0.39, 0.86) or 0.27 (0.14, 0.51)) and postmenopausal women (OR (95% CI): 0.43 (0.29, 0.65) or 0.53 (0.28, 0.99)). Subjects with high progesterone and low Chr17:76,356,190 or Chr17:76,356,199 methylation were more susceptible to have a higher prevalence of T2DM (men: OR (95% CI): 5.20 (2.49, 10.85) or 5.62 (2.74, 11.54); postmenopausal women: OR (95% CI): 3.66 (1.85, 7.26) or 3.27 (1.66, 6.45)).
CONCLUSIONS
The independent and combined effects of progesterone and SOCS3 methylation on T2DM were found among men and postmenopausal women, suggesting that ensuring low levels of progesterone and high methylation of SOCS3 could reduce the prevalence of T2DM. Trial registration The Chinese Clinical Trial registration: The Henan Rural Cohort Study, ChiCTR-OOC-15006699. Registered 06 July 2015, http://www.chictr.org.cn/showproj.aspx?proj=11375.
Identifiants
pubmed: 34565450
doi: 10.1186/s13148-021-01172-9
pii: 10.1186/s13148-021-01172-9
pmc: PMC8474856
doi:
Substances chimiques
SOCS3 protein, human
0
Suppressor of Cytokine Signaling 3 Protein
0
Progesterone
4G7DS2Q64Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Subventions
Organisme : the national key research and development program of china
ID : 2016YFC0900803
Organisme : the national key research and development program of china
ID : 2019YFC1710002
Organisme : the national natural science foundation of china
ID : 21806146
Organisme : the postdoctoral science foundation of china
ID : 2016M602264
Organisme : the postdoctoral science foundation of china
ID : 2020T130604
Organisme : the excellent youth development foundation of zhengzhou university
ID : 2018ZDGGJS052
Organisme : the science and technique foundation of henan province
ID : 202102310046
Informations de copyright
© 2021. The Author(s).
Références
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15644-8
pubmed: 12438645
Hormones (Athens). 2019 Jun;18(2):127-136
pubmed: 30414080
Gend Med. 2009 Sep;6(3):433-43
pubmed: 19850239
Diabetologia. 2019 Sep;62(9):1591-1600
pubmed: 31093692
Lancet. 2021 Mar 27;397(10280):1183-1194
pubmed: 33773630
J Diabetes Investig. 2020 Jan;11(1):241-249
pubmed: 31172682
Diabetes. 2013 Jan;62(1):56-64
pubmed: 22961088
Contraception. 2004 Mar;69(3):251-7
pubmed: 14969675
Metabolism. 2007 Jun;56(6):830-7
pubmed: 17512317
Diabetes. 2010 Oct;59(10):2625-30
pubmed: 20682697
J Diabetes. 2021 Sep;13(9):701-712
pubmed: 33576141
Diabetes Care. 2009 Jan;32 Suppl 1:S62-7
pubmed: 19118289
Nutrients. 2020 Dec 30;13(1):
pubmed: 33396618
Exp Mol Med. 2016 Mar 11;48:e220
pubmed: 26964836
FASEB J. 2020 Oct;34(10):13548-13560
pubmed: 32786125
Trends Endocrinol Metab. 2017 Jul;28(7):497-505
pubmed: 28416361
Nutr Metab Cardiovasc Dis. 2020 Apr 12;30(4):634-643
pubmed: 31848053
J Diabetes Res. 2019 Nov 19;2019:5320156
pubmed: 31828161
Eur J Endocrinol. 2019 Dec;181(6):603-614
pubmed: 31581126
Nature. 2001 Dec 13;414(6865):799-806
pubmed: 11742412
Endocrinology. 2008 Jun;149(6):3206-14
pubmed: 18325991
Curr Biol. 2003 Jul 15;13(14):R574-6
pubmed: 12867054
Diabetologia. 2012 Nov;55(11):3083-93
pubmed: 22872213
Acta Physiol (Oxf). 2008 Jan;192(1):29-36
pubmed: 18171427
J Endocrinol. 2014 Apr 22;221(2):273-84
pubmed: 24594616
Theranostics. 2018 Nov 9;8(20):5593-5609
pubmed: 30555566
Nature. 2015 Jul 9;523(7559):212-6
pubmed: 26030523
Int J Epidemiol. 2019 Dec 1;48(6):1756-1756j
pubmed: 30915440
Pharmacol Ther. 2007 Oct;116(1):77-106
pubmed: 17659348
Metabolism. 2009 Feb;58(2):239-45
pubmed: 19154958
Mol Cell Biol. 2004 Jun;24(12):5434-46
pubmed: 15169905
Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E881-8
pubmed: 20071559
J Biol Chem. 2002 Nov 1;277(44):42394-8
pubmed: 12228220
Medicine (Baltimore). 2017 Jun;96(26):e7378
pubmed: 28658166
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Mol Med Rep. 2015 Jul;12(1):83-92
pubmed: 25695729
Diabetes Care. 2004 Jun;27(6):1487-95
pubmed: 15161807
Endocrinology. 1993 Nov;133(5):2227-34
pubmed: 8404674
Obstet Gynecol. 2009 Jul;114(1):45-49
pubmed: 19546757
Lancet Diabetes Endocrinol. 2015 Jul;3(7):526-534
pubmed: 26095709
J Cardiovasc Med (Hagerstown). 2019 Sep;20(9):575-583
pubmed: 31246698
ISRN Endocrinol. 2012;2012:965243
pubmed: 22852093
Epigenetics. 2017 Jun 3;12(6):401-415
pubmed: 28059593